CLAR:NASDAQClarus Corporation Analysis
Data as of 2026-03-14 - not real-time
$2.78
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Clarus Corp (CLAR) is trading at $2.78, which sits below its 20‑day ($3.15) and 50‑day ($3.42) simple moving averages and is in a bearish zone according to the MACD (line = ‑0.15, signal = ‑0.12). The RSI of 28.6 indicates the stock is oversold, while the 30‑day volatility of roughly 44% and a beta near 0.9 highlight heightened price swings for a small‑cap consumer‑cyclical player. The DCF fair value of $1.98 suggests the market price is significantly above intrinsic estimates, implying an overvaluation gap of about 40% upside/downside. Despite these technical headwinds, the company posted a non‑GAAP EPS of $0.09 in Q4 2025, beating consensus by 38.5%, and insiders have increased their stakes over the past year, signaling confidence in a turnaround.
The dividend yield of 3.6% with a modest 14.7% payout ratio, positive free cash flow of $3.8 M, and a low price‑to‑book of 0.54 provide a value cushion, while cost‑cutting initiatives and international expansion aim to revive revenue, which fell 8.4% YoY. However, operating margins remain negative and revenue growth is still declining, so the upside hinges on the company’s ability to convert its restructuring efforts into sustainable top‑line growth.
The dividend yield of 3.6% with a modest 14.7% payout ratio, positive free cash flow of $3.8 M, and a low price‑to‑book of 0.54 provide a value cushion, while cost‑cutting initiatives and international expansion aim to revive revenue, which fell 8.4% YoY. However, operating margins remain negative and revenue growth is still declining, so the upside hinges on the company’s ability to convert its restructuring efforts into sustainable top‑line growth.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Oversold technicals (RSI <30) and price near support
- Quarterly earnings beat and insider buying
- Attractive dividend yield with low payout
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Ongoing cost‑reduction and international expansion plans
- Negative operating margins and declining revenue trend
- Valuation still above intrinsic fair value
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Fundamental turnaround risk given current profitability profile
- Sustainable dividend provides income buffer
- Sector cyclicality may limit growth prospects
Key Metrics & Analysis
Financial Health
Revenue Growth-8.40%
Profit Margin-18.59%
P/E Ratio11.3
ROE-21.68%
ROA-5.08%
Debt/Equity6.26
P/B Ratio0.5
Op. Cash Flow$-4746000
Free Cash Flow$3.8M
Technical Analysis
TrendBearish
RSI28.6
Support$2.74
Resistance$3.47
MA 20$3.15
MA 50$3.42
MA 200$3.48
MACDBearish
VolumeStable
Fear & Greed Index72.88
Valuation
Fair Value$1.98
Target Price$3.85
Upside/Downside38.74%
GradeOvervalued
TypeValue
Dividend Yield3.60%
Risk Assessment
Beta0.91
Volatility44.63%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.